Second-line chemotherapy in 54 patients with sensitive or refractory small cell lung cancer

LUO Mei-qing; et al

doi:10.13406/j.cnki.cyxb.2010.09.042

您当前的位置：

首页 >

文章列表页 >

Second-line chemotherapy in 54 patients with sensitive or refractory small cell lung cancer

更新时间：2024-01-17

- Second-line chemotherapy in 54 patients with sensitive or refractory small cell lung cancer
- Journal of Chongqing Medical University Vol. 35, Issue 9, Pages: 1430-1432(2010)
- 作者机构：
  
  桂林医学院附属医院肿瘤内科
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.2010.09.042
  CLC： R734.2
- Published：2010，
扫描看全文
[1]骆梅青,康马飞,廖漓漓,刘瑛,董翠梅.54例小细胞肺癌二线化疗的临床研究[J].重庆医科大学学报,2010,35(09):1430-1432+1438.

LUO Mei-qing, et al. Second-line chemotherapy in 54 patients with sensitive or refractory small cell lung cancer. [J]. Journal of Chongqing Medical University 35(9):1430-1432(2010)
[1]骆梅青,康马飞,廖漓漓,刘瑛,董翠梅.54例小细胞肺癌二线化疗的临床研究[J].重庆医科大学学报,2010,35(09):1430-1432+1438. DOI： 10.13406/j.cnki.cyxb.2010.09.042.

LUO Mei-qing, et al. Second-line chemotherapy in 54 patients with sensitive or refractory small cell lung cancer. [J]. Journal of Chongqing Medical University 35(9):1430-1432(2010) DOI： 10.13406/j.cnki.cyxb.2010.09.042.

摘要

目的:探讨敏感复发及耐药复发的小细胞肺癌（Small cell lung cancer

SCLC）的二线化疗方案及疗效。方法:2004年1月～2009年1月收治经足叶乙甙联合铂类一线化疗后复发的小细胞肺癌共54例

其中敏感复发患者26例

耐药复发患者28例。对耐药复发或敏感复发时间不足6个月者

采用紫杉类或伊立替康单药化疗;对敏感复发时间6个月或6个月以上者仍采用原一线方案化疗。结果:54例患者二线化疗总有效率18.5%

中位疾病进展时间（mTTP）20.2周

中位生存期（MST）11.5个月。敏感复发组及耐药复发组的有效率（CR+PR）分别为30.8%和7.1%（P=0.009）

mTTP分别为24.5周和15.8周（P=0.001）

MST分别为13.0个月和9.0个月（P=0.003）。骨髓抑制为二线化疗的主要不良反应

敏感复发组及耐药复发组Ⅲ～Ⅳ级白细胞减少发生率分别为34.6%和39.3%

Ⅲ～Ⅳ级血小板减少发生率分别为15.4%和17.9%

两组不良反应无明显差异（P>0.05）。结论:足叶乙甙联合铂类一线化疗后复发的小细胞肺癌采用二线化疗有部分病例仍有效

敏感复发患者的近期疗效和生存期均优于耐药复发患者。

Abstract

Objective:To investigate the benefit of second-line chemotherapy for sensitive or refractory small cell lung cancer after primary treatment with platinum and etoposide.Methods:From January 2004 to January 2009

54 patients were treated with second-line chemotherapy:26 patients with sensitive(S) disease(recurred > 3 months after first-line chemotherapy) and 28 patients with refractory(R) disease(recurred < 3 months after first-line chemotherapy).Patients with R disease or S disease but failed < 6 months after first-line chemotherapy received paclitaxel or docetaxel or irinotecan

and patients with S disease and failed > 6 months after first-line chemotherapy were retreated with the same regimen.Results:54 patients received second-line chemotherapy.The response rate to second-line chemotherapy was 30.8% in S group

7.1% in R group(P=0.009)

and 18.5% for the whole group.The medium times for progression(mTTP) were 24.5 weeks in S group

15.8 weeks in R group

and 20.2 weeks for all patients(P=0.001).The medium survivals were 13.0 months in S group

9.0 months in R group(P=0.003)

and 11.5 months for all patients.Myelosuppression was the most commonly observed adverse effect.Grade 3 /4 neutropenia and thrombocytopenia accounted for 34.6% and 15.4%

respectively

in S group

39.3% and 17.9%

respectively

in R group.There was not significant difference in side effect between S and R group.Conclusion:Second-line chemotherapy for relapsed SCLC patients after platinum compound etoposide is clinically effective.Patients with S disease had higher response rate and a longer survival time than the patients with R disease.

关键词

小细胞肺癌敏感性耐药性二线化疗

Keywords

small cell lung cancerSensitiveRefractorySecond-line chemotherapy

references

Views

117

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of prognostic factors and clinical characteristics of patients with small cell lung cancer with malignant pericardial effusion

Efficacy of carboplatin plus etoposide as second-line treatment on 17 patients with small cell lung cancer

Evaluation of postoperative radiotherapy in limited-stage small cell lung cancer with propensity score matching analysis

Related Author

Hao Yang

Tonghua Mei

SU Yi

Yang Hao

Mei Tonghua

Related Institution

Department of Respiratory and Critical Care Medicine,The First Affiliated Hospital of Chongqing Medical University

Department of Respiratory Diseases,the First Affiliated Hospital,Chongqing Medical University

Department of Respiratory and Critical Care Medicine，The First Affiliated Hospital of Chongqing Medical University

⁰